Health Catalyst, Inc Common Stock earnings per share and revenue
On Nov 10, 2025, HCAT reported earnings of 0.06 USD per share (EPS) for Q3 25, missing the estimate of 0.06 USD, resulting in a -0.66% surprise. Revenue reached 76.32 million, compared to an expected 77.42 million, with a -1.41% difference. The market reacted with a -5.61% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analysts forecast an EPS of 0.09 USD, with revenue projected to reach 75.46 million USD, implying an increase of 50.00% EPS, and decrease of -1.13% in Revenue from the last quarter.
FAQ
What were Health Catalyst, Inc Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Health Catalyst, Inc Common Stock reported EPS of $0.06, missing estimates by -0.66%, and revenue of $76.32M, -1.41% below expectations.
How did the market react to Health Catalyst, Inc Common Stock's Q3 2025 earnings?
The stock price moved down -5.61%, changed from $2.85 before the earnings release to $2.69 the day after.
When is Health Catalyst, Inc Common Stock expected to report next?
The next earning report is scheduled for Feb 24, 2026.
What are the forecasts for Health Catalyst, Inc Common Stock's next earnings report?
Based on 12
analysts, Health Catalyst, Inc Common Stock is expected to report EPS of $0.09 and revenue of $75.46M for Q4 2025.